Biological treatments used for psoriasis, such as TNF-α inhibitors (e.g., etanercept, adalimumab, or infliximab), IL-17 inhibitors (e.g., secukinumab or ixekizumab), and IL-23 inhibitors (e.g., ustekinumab or guselkumab), have been shown to modulate various aspects of the immune response’s involvement in the pathogenesis of psoriasis [24]. The gene discussed is IL17A; the disease is psoriasis.